questionText: To ask the Secretary of State for Health and Social Care, if he will make representations to (a) Daiichi Sankyo and (b) AstraZeneca following the decision by NICE not to recommend Enhertu as a cost effective treatment for advanced stage breast cancer.
answerText: Decisions on whether new medicines should be routinely funded by the National Health Service in England are taken by the National Institute for Health and Care Excellence (NICE), on the basis of an evaluation of a treatment’s costs and benefits. The NICE’...
heading: Trastuzumab Deruxtecan